News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
George Vlachogiannis: Artak Heboyan and colleagues on the cytotoxicity of nanocarrier-based drug
Collage Photo of Artak Heboyan and George Vlachogiannis
Jan 22, 2025, 08:05

George Vlachogiannis: Artak Heboyan and colleagues on the cytotoxicity of nanocarrier-based drug

George Vlachogiannis, Executive Editor of Cancer Control at Sage Publishing, posted on LinkedIn about recent paper by Artak Heboyan  et al., titled “Cytotoxicity of Nanocarrier-Based Drug Delivery in Oral Cancer Therapy: A Systematic Review and Meta-Analysis” published on Sage Journal.

Authors: Mohammad A. Saghiri, Ravinder S. Saini, Artak Heboyan

George Vlachogiannis: Artak Heboyan and colleagues on the cytotoxicity of nanocarrier-based drug

“Systematic review by Dr Artak Heboyan and colleagues on the cytotoxicity of nanocarrier-based drug delivery for oral cancer therapy. The meta-analysis indicates enhanced treatment efficacy, reduced toxicity, and improved drug targeting compared to conventional methods. Manuscript out in Cancer Control.”

 

Artak Heboyan cancer George Vlachogiannis OncoDaily Oncology oral cancer therapy Sage Journal
Special Coverage
Blog
Jan 23, 2025, 09:26
Rajkumar Venkatramani: I crossed the finish line at the Houston Half Marathon
Career
Jan 23, 2025, 09:22
Nirali Shah was elected to the American Society of Clinical Investigation - NCI Center for Cancer Research
Blog
Jan 23, 2025, 09:09
Sean Khozin: Grateful to have joined the Richard Nixon Foundation Cancer Conference
Insight
Jan 23, 2025, 09:08
How Egypt is closing the gap in breast cancer care: Dr. Hesham El-Ghazaly leads the conversation
Blog
Jan 23, 2025, 09:06
David Lee: Staying true to our purpose at Servier Pharmaceuticals
Blog
Jan 23, 2025, 09:03
Key anatomical imaging features can provide complementary information for differentiating high-risk from non-high-risk neuroblastoma
Insight
Jan 23, 2025, 06:31
Highlights from DESTINY-Breast06 trial presented at the 17th BGICC by Giuseppe Curigliano
Insight
Jan 23, 2025, 05:20
The 17th Annual BGICC Conference Kicks Off in Cairo, Egypt with 5,000 Attendees
Blog
Jan 23, 2025, 02:32
Tedros Adhanom Ghebreyesus: A productive discussion with President Samia Suluhu
Blog
Jan 23, 2025, 02:32
European School of Oncology - Attend the Fourth Online Course of the CCI4EU series on 28 February 2025
Blog
Jan 23, 2025, 02:32
Rob Winn: Eliminating the cancer burden and ensuring that the miracle medicine reaches every community
Blog
Jan 23, 2025, 02:32
Children's Cancer Institute - Cancer Australia consulted on the Draft National Framework for Genomics in Cancer Control